Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report

Autor: Sidney H. Kennedy, Wendy Lou, Sagar V. Parikh, Raymond W. Lam, Susan Rotzinger, Emma Morton, Peter Giacobbe, Daniel J. Müller, Erin E. Michalak, Roumen Milev, Can-Bind Investigator Team, Trisha Chakrabarty, Benicio N. Frey, Venkat Bhat
Rok vydání: 2021
Předmět:
Zdroj: Pharmacopsychiatry. 54:225-231
ISSN: 1439-0795
0176-3679
Popis: Introduction Many individuals with major depressive disorder (MDD) do not respond to initial antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non-response; however, the impacts on quality of life (QoL) for individuals who receive this second-line treatment strategy have not been described. Methods We evaluated secondary QoL outcomes in patients with MDD (n=179). After 8 weeks of escitalopram, non-responders ( Results Escitalopram responders experienced the most QoL improvements in the first treatment phase. For non-responders, QoL improved with a large effect during adjunctive aripiprazole treatment. At the endpoint, 47% of patients achieving symptomatic remission still had impaired QoL. Discussion Individuals who were treated with adjunctive aripiprazole after non-response to escitalopram experienced improved QoL, but a substantial degree of QoL impairment persisted. Since QoL deficits may predict MDD recurrence, attention to ways to support this outcome is required.
Databáze: OpenAIRE